LENZ Therapeutics is a commercial-stage biopharmaceutical company that specializes in the development and distribution of innovative, non-invasive ophthalmic pharmaceutical products. Its premier commercial asset is VIZZ (aceclidine ophthalmic solution 1.44%), a groundbreaking once-daily eye drop formulated to improve near vision in adults suffering from presbyopia by utilizing a pupil-selective miotic mechanism of action.